The biology of VEGF and its receptors
The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Ferrara et al., 2003
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 1×
“VEGF induces a potent angiogenic response in a variety of in vivo model”
BackgroundSelf-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Self-citationMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972 · cited 1×
“VEGF is known also as vascular permeability factor, based on its ability to induce vascular leakag”
BackgroundFailure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Self-citationVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Many molecules have been implicated as positive regulators of angiogenesis, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-α, TGF-β, hepatocyte growth factor (HGF, or scatter factor), tumor necrosis factor-α, angiogenin, interleukin (IL)-8 and the angiopoietin”
Background
Research works printed but not linked: 3
- Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
- Yang, J.C. et al. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Engl. J. Med. (in the press).
Cited by
Items 401–500 of 1,056
McElwain, C. J., Tuboly, E., McCarthy, F. P., & McCarthy, C. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00655 · Cited by 208
“Whereas, VEGF can bind to various receptors including VEGFR-1, 2, and 3, PIGF specifically signals through VEGFR-1 (or Flt-1) binding (155).”
BackgroundDiabetic macular edema: new concepts in patho-physiology and treatment
Zhang, X., Zeng, H., Bao, S., Wang, N., & Gillies, M. C. (2014) · Cell & Bioscience · doi:10.1186/2045-3701-4-27 · Cited by 230
“It has been well accepted that FLK-1 is the principle mediator of VEGF-A’s effect on vascular permeability and angiogenesis [46].”
BackgroundHsieh, S. H., Ying, N. W., Wu, M. H., Chiang, W. F., Hsu, C. L., Wong, T. Y., Jin, Y. T., Hong, T. M., & Chen, Y. L. (2008) · Oncogene · doi:10.1038/sj.onc.1211029 · Cited by 229
“Vascular endothelial growth factor receptors (VEGFRs), including VEGFR-1, VEGFR-2, VEGFR-3 and neuropilins, are key mediators of angiogenesis and lymphangiogenesis (Ferrara et al., 2003), and are all glycoproteins.”
BackgroundInfluentialTamura, R., Tanaka, T., Akasaki, Y., Murayama, Y., Yoshida, K., & Sasaki, H. (2020) · Medical Oncology · doi:10.1007/s12032-019-1329-2 · Cited by 226
“Since discovery of its dual roles in endothelial proliferation and vascular permeability [18, 19], VEGF has been considered a key mediator of neovascularization in tumors (Fig.”
BackgroundCarbajo-Pescador, S., Ordoñez, R., Benet, M., Jover, R., García-Palomo, A., Mauriz, J. L., & González-Gallego, J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.285 · Cited by 233
“Vascular endothelial growth factor is a secreted protein that acts as a potent mitogen for vascular endothelial cells and some other cell types, being one of the main regulatory factors in angiogenesis and neovascularisation (Ferrara et al, 2003).”
BackgroundLos, M., Roodhart, J. M. L., & Voest, E. E. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-443 · Cited by 229
“VEGF binds with high affinity to the transmembrane tyrosine kinase receptors VEGFR-1, -2, and -3 [ 5 ].”
BackgroundArvizo, R. R., Rana, S., Miranda, O. R., Bhattacharya, R., Rotello, V. M., & Mukherjee, P. (2011) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.01.011 · Cited by 229
“portent among its several isoforms, is a heparin binding protein [5].”
BackgroundTheilgaard-Mönch, K., Knudsen, S., Follin, P., & Borregaard, N. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7684 · Cited by 227
Cafestol and Kahweol: A Review on Their Bioactivities and Pharmacological Properties
Ren, Y., Wang, C., Xu, J., & Wang, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174238 · Cited by 209
“Their study showed that both CP and KP at 50 µM inhibited the proliferation and migration of HMVECs through down-regulating the expression of VEGFR2 and Akt.”
BackgroundInfluentialAntiangiogenic therapy for cancer: current and emerging concepts.
Coiffier, B., & Reyes, F. (2005) · PubMed · Cited by 231
Neuropilin-1 Binds to VEGF121 and Regulates Endothelial Cell Migration and Sprouting
Pan, Q., Chathery, Y., Wu, Y., Rathore, N., Tong, R. K., Peale, F., Bagri, A., Tessier-Lavigne, M., Koch, A. W., & Watts, R. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703554200 · Cited by 204
Multi‐targeted therapy by curcumin: how spicy is it?
Goel, A., Jhurani, S., & Aggarwal, B. B. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700354 · Cited by 228
VEGF Inhibition, Hypertension, and Renal Toxicity
Hayman, S. R., Leung, N., Grande, J. P., & Garovic, V. D. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0242-z · Cited by 230
Structural basis for ligand and heparin binding to neuropilin B domains
Vander Kooi, C. W., Jusino, M. A., Perman, B., Neau, D. B., Bellamy, H. D., & Leahy, D. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700043104 · Cited by 227
Axl is essential for VEGF‐A‐dependent activation of PI3K/Akt
Ruan, G., & Kazlauskas, A. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.21 · Cited by 223
“Many pro-angiogenic effects of VEGF-A are mediated by VEGF receptor 2 (VEGFR-2, also known as KDR or Flk-1) (Ferrara et al , 2003; Holmes et al , 2007).”
Pathology and new players in the pathogenesis of brain edema
Nag, S., Manias, J. L., & Stewart, D. J. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0541-0 · Cited by 227
“permeability-enhancing effects of VEGF-A [51].”
BackgroundPoldervaart, M. T., Gremmels, H., van Deventer, K., Fledderus, J. O., Öner, F. C., Verhaar, M. C., Dhert, W. J. A., & Alblas, J. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.007 · Cited by 224
Jüttner, S., Wiβmann, C., Jöns, T., Vieth, M., Hertel, J., Gretschel, S., Schlag, P. M., Kemmner, W., & Höcker, M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.3467 · Cited by 228
Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities
Estrada, C. C., Maldonado, A., & Mallipattu, S. K. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018080853 · Cited by 221
Kim, S., Chung, M., Ahn, J., Lee, S., & Jeon, N. L. (2016) · Lab on a Chip · doi:10.1039/c6lc00910g · Cited by 227
Markowska, A. I., Jefferies, K. C., & Panjwani, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.226423 · Cited by 218
Drug delivery approaches for breast cancer
Singh, S., Singh, S., Lillard Jr, J. W., & Singh, R. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s140325 · Cited by 219
Angiopoietins in tumours: the angiogenic switch
Tait, C. R., & Jones, P. F. (2004) · The Journal of Pathology · doi:10.1002/path.1618 · Cited by 223
Amin, D. N., Hida, K., Bielenberg, D. R., & Klagsbrun, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3387 · Cited by 220
“survival, proliferation, and migration (11).”
Breen, E. C. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21579 · Cited by 220
“…the functional role of this angiogenic factor in the regulation of vasculogenesis, the differentiation and organization of endothelial progenitor cells into a primary capillary plexus, and angiogenesis, the formation of new capillaries from preexisting vessels [reviewed in Ferrara et al., 2003].”
InfluentialAntiangiogenic Therapy for Cancer: An Update
Al‐Husein, B., Abdalla, M., Trepte, M., DeRemer, D. L., & Somanath, P. R. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1147 · Cited by 216
Brown, D. M., & Regillo, C. D. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.06.039 · Cited by 224
Harrington, L. S., Sainson, R. C. A., Williams, C. K., Taylor, J. M., Shi, W., Li, J.-L., & Harris, A. L. (2008) · Microvascular Research · doi:10.1016/j.mvr.2007.06.006 · Cited by 215
“PlGF can stimulate angiogenesis possibly by displacing VEGF from VEGFR1 (Ferrara et al., 2003).”
InfluentialChae, S.-S., Paik, J.-H., Furneaux, H., & Hla, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422716 · Cited by 220
“For example, the VEGF gene is not only critical for the various phases of embryonic vascular development but is also important in tumor angiogenesis (9).”
BackgroundNovo, E., Cannito, S., Zamara, E., di Bonzo, L. V., Caligiuri, A., Cravanzola, C., Compagnone, A., Colombatto, S., Marra, F., Pinzani, M., et al. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060887 · Cited by 220
Angiopoietin-2 Causes Inflammation in Vivo by Promoting Vascular Leakage
Roviezzo, F., Tsigkos, S., Kotanidou, A., Bucci, M., Brancaleone, V., Cirino, G., & Papapetropoulos, A. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.086553 · Cited by 221
“sel structures (Ferrara et al., 2003; Zachary, 2003).”
BackgroundNeovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
Ricci, F., Bandello, F., Navarra, P., Staurenghi, G., Stumpp, M., & Zarbin, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218242 · Cited by 208
“The VEGF gene encodes a family of glycoproteins, whose primary function is the formation of blood vessels de novo (vasculogenesis, as occurs in embryonic development) and angiogenesis (formation of new blood vessels from preexisting vessels) by activating cellular signal pathways [62].”
BackgroundWang, N., Wang, Z.-Y., Mo, S.-L., Loo, T. Y., Wang, D.-M., Luo, H.-B., Yang, D.-P., Chen, Y.-L., Shen, J.-G., & Chen, J.-P. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-1977-9 · Cited by 210
“Considering antiangiogenesis therapy is to target endothelial cells that support tumor growth rather than cancer cells themselves, VEGFR-2 has become an important therapeutic target for cancer anti-angiogenesis therapy [7–10].”
BackgroundParacrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis
Kälin, R. E., Kretz, M. P., Meyer, A. M., Kispert, A., Heppner, F. L., & Brändli, A. W. (2007) · Developmental Biology · doi:10.1016/j.ydbio.2007.03.004 · Cited by 217
Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature
Shen, J., Frye, M., Lee, B. L., Reinardy, J. L., McClung, J. M., Ding, K., Kojima, M., Xia, H., Seidel, C., Silva, R. L. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74527 · Cited by 217
“Over the past several years, there has been considerable progress in elucidating molecular mechanisms involved in pathologic angiogenesis and excessive vascular leakage, and it is well established that VEGF plays an important role (1, 2).”
Exercise‐Induced Capillary Growth in Human Skeletal Muscle and the Dynamics of VEGF
Hoier, B., & Hellsten, Y. (2014) · Microcirculation · doi:10.1111/micc.12117 · Cited by 215
“VEGF165 is a homodimeric heparin-binding glycosylated protein with a molecular weight of ~42kD with VEGF receptor and heparan-sulfate proteoglycan binding affinities [25,60,66,68,95].”
BackgroundMCP-1 mediates TGF-β–induced angiogenesis by stimulating vascular smooth muscle cell migration
Ma, J., Wang, Q., Fei, T., Han, J.-D. J., & Chen, Y.-G. (2007) · Blood · doi:10.1182/blood-2006-07-036400 · Cited by 213
Angiogenesis in chronic inflammatory liver disease
Medina, J., Arroyo, A. G., Sánchez-Madrid, F., & Moreno-Otero, R. (2004) · Hepatology · doi:10.1002/hep.20193 · Cited by 219
Nakamura, K., Taguchi, E., Miura, T., Yamamoto, A., Takahashi, K., Bichat, F., Guilbaud, N., Hasegawa, K., Kubo, K., Fujiwara, Y., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4290 · Cited by 207
“However, this may not be an important consideration as it seems that the major angiogenic signals elicited by VEGF are mediated by the VEGFR-2 homodimer complex (1).”
BackgroundAbraldes, J. G., Iwakiri, Y., Loureiro-Silva, M., Haq, O., Sessa, W. C., & Groszmann, R. J. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00336.2005 · Cited by 214
“It has been shown that one important stimulus for VEGF expression is tissue hypoxia (13).”
BackgroundPodar, K., Tonon, G., Sattler, M., Tai, Y.-T., LeGouill, S., Yasui, H., Ishitsuka, K., Kumar, S., Kumar, R., Pandite, L. N., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609329103 · Cited by 216
Anti-Angiogenics: Current Situation and Future Perspectives
Zirlik, K., & Duyster, J. (2018) · Oncology Research and Treatment · doi:10.1159/000488087 · Cited by 216
A review about the development of fucoidan in antitumor activity: Progress and challenges
Wu, L., Sun, J., Su, X., Yu, Q., Yu, Q., & Zhang, P. (2016) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2016.08.005 · Cited by 212
Allaman, I., Fiumelli, H., Magistretti, P. J., & Martin, J.-L. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2190-y · Cited by 209
“VEGF was originally described as an endothelial cell mitogen and survival factor that regulates angiogenesis and vascular permeability ( Ferrara et al. 2003 ).”
BackgroundExamination of the foreign body response to biomaterials by nonlinear intravital microscopy
Dondossola, E., Holzapfel, B. M., Alexander, S., Filippini, S., Hutmacher, D. W., & Friedl, P. (2016) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0007 · Cited by 215
Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis
Lee, S. H., Jeong, D., Han, Y.-S., & Baek, M. J. (2015) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2015.89.1.1 · Cited by 210
Savant, S., Sriramkumar, S., & O’Hagan, H. (2018) · Cancers · doi:10.3390/cancers10080251 · Cited by 209
“The rate-limiting step in angiogenesis is VEGF signaling in endothelial cells (ECs) [135].”
BackgroundTrends and Challenges in Tumor Anti-Angiogenic Therapies
Jászai, J., & Schmidt, M. (2019) · Cells · doi:10.3390/cells8091102 · Cited by 208
“This substantially modifies the spreading and biological availability of certain members of this secreted growth factor family [14,15,79, 90,95,96].”
BackgroundReceptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches
Saraon, P., Pathmanathan, S., Snider, J., Lyakisheva, A., Wong, V., & Stagljar, I. (2021) · Oncogene · doi:10.1038/s41388-021-01841-2 · Cited by 205
“tions and acts on VEGFR receptors expressed on endothelial cells to promote tumor angiogenesis [33], and PDGF”
BackgroundLafky, J. M., Wilken, J. A., Baron, A. T., & Maihle, N. J. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.01.001 · Cited by 215
Díaz-Rubio, E., Gómez-España, A., Massutí, B., Sastre, J., Abad, A., Valladares, M., Rivera, F., Safont, M. J., Martínez de Prado, P., Gallén, M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0249 · Cited by 210
“Bevacizumab is a humanized monoclonal antibody that inhibits vascular endothelial growth factor [7, 8] and has been shown to result in longer progression-free survival (PFS) and overall survival (OS) times when combined with chemotherapy for the treatment of patients with mCRC in the first- and second-line settings [4…”
BackgroundEbos, J. M. L., Bocci, G., Man, S., Thorpe, P. E., Hicklin, D. J., Zhou, D., Jia, X., & Kerbel, R. S. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.315.2.6 · Cited by 211
“The VEGF family consists of VEGF-A (also called VEGF), VEGF-B, VEGF-C, and VEGF-D as well as placental growth factor (6).”
BackgroundAngiogenesis in Wounds Treated by Microdeformational Wound Therapy
Erba, P., Ogawa, R., Ackermann, M., Adini, A., Miele, L. F., Dastouri, P., Helm, D., Mentzer, S. J., D’Amato, R. J., Murphy, G. F., et al. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31820563a8 · Cited by 207
Marrelli, A., Cipriani, P., Liakouli, V., Carubbi, F., Perricone, C., Perricone, R., & Giacomelli, R. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.04.020 · Cited by 205
“VEGF is produced in response to stimulation by proinflammatory cytokines (interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-alpha, transforming growth factor (TGF)-beta) from perivascular cells and, in RA it is regulated also by the physical interaction of activated leukocytes and fibroblast-like synoviocytes and…”
BackgroundThe VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path Forward
Kieran, M. W., Kalluri, R., & Cho, Y.-J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006593 · Cited by 206
“Furthermore, alternative splice variants of VEGF have been identified including VEGF121, VEGF165, VEGF189, and VEGF206, each with a different primary role (Ferrara et al. 2003).”
BackgroundShah, M. A., Wainberg, Z. A., Catenacci, D. V. T., Hochster, H. S., Ford, J., Kunz, P., Lee, F.-C., Kallender, H., Cecchi, F., Rabe, D. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054014 · Cited by 208
“VEGFR2 mediates endothelial cell migration, proliferation and survival [19,20], and MET and VEGFR2 work in concert to promote neoangiogenesis [20].”
Duman, R. S. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.3/rsduman · Cited by 210
Fukushima, Y., Okada, M., Kataoka, H., Hirashima, M., Yoshida, Y., Mann, F., Gomi, F., Nishida, K., Nishikawa, S.-I., & Uemura, A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44900 · Cited by 207
“Based on these findings, we propose that Sema3E-PlexinD1 signaling acts as a negative feedback system against VEGF signaling in terms of the filopodia projections as follows: Under hypoxia, VEGF evokes a series of proangiogenic signaling cascades for proliferation, survival, and migration (36) but simultaneously upreg…”
BackgroundEstrogen Receptor β Inhibits Angiogenesis and Growth of T47D Breast Cancer Xenografts
Hartman, J., Lindberg, K., Morani, A., Inzunza, J., Ström, A., & Gustafsson, J.-A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0017 · Cited by 206
“The most important factors in tumor angiogenesis are VEGF, bFGF, PDGFh, and angiopoietins ( 22 , 23).”
BackgroundBioavailability of VEGF in Tumor-Shed Vesicles Depends on Vesicle Burst Induced by Acidic pH
Taraboletti, G., D'Ascenzoy, S., Giusti, I., Marchetti, D., Borsotti, P., Millimaggi, D., Giavazzi, R., Pavan, A., & Dolo, V. (2006) · Neoplasia · doi:10.1593/neo.05583 · Cited by 199
Non-thermal dielectric barrier discharge plasma induces angiogenesis through reactive oxygen species
Arjunan, K. P., Friedman, G., Fridman, A., & Clyne, A. M. (2012) · Journal of The Royal Society Interface · doi:10.1098/rsif.2011.0220 · Cited by 207
Fons, P., Chabot, S., Cartwright, J. E., Lenfant, F., L'Faqihi, F., Giustiniani, J., Herault, J.-P., Gueguen, G., Bono, F., Savi, P., et al. (2006) · Blood · doi:10.1182/blood-2005-12-019919 · Cited by 200
Huang, Y., Shi, H., Zhou, H., Song, X., Yuan, S., & Luo, Y. (2006) · Blood · doi:10.1182/blood-2005-07-2961 · Cited by 205
Overview of current targeted therapy in gallbladder cancer
Song, X., Hu, Y., Li, Y., Shao, R., Liu, F., & Liu, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00324-2 · Cited by 202
Abou Khouzam, R., Brodaczewska, K., Filipiak, A., Zeinelabdin, N. A., Buart, S., Szczylik, C., Kieda, C., & Chouaib, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613114 · Cited by 198
“Moreover, markers of hypoxia such as HIF-1a and VEGF-A were dramatically reduced by O2 delivery ITPP-loaded RBCs upon rolling onto the endothelial cell layer in hypoxic conditions.”
BackgroundInfluentialAroeira, L. S., Aguilera, A., Selgas, R., Ramírez-Huesca, M., Pérez-Lozano, M. L., Cirugeda, A., Bajo, M. A., del Peso, G., Sánchez-Tomero, J. A., Jiménez-Heffernan, J. A., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.08.011 · Cited by 208
Hif-1α regulates differentiation of limb bud mesenchyme and joint development
Provot, S., Zinyk, D., Gunes, Y., Kathri, R., Le, Q., Kronenberg, H. M., Johnson, R. S., Longaker, M. T., Giaccia, A. J., & Schipani, E. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200612023 · Cited by 198
“To investigate whether removal of Hif-1α in limb bud mesenchyme would alter angiogenesis with yet unknown mechanisms, we then analyzed the expression of VEGF-receptor2 (VEGFR2), which is a marker of endothelial cells (Ferrara et al., 2003).”
BackgroundMechanisms of Hyperbaric Oxygen-Induced Neuroprotection in a Rat Model of Subarachnoid Hemorrhage
Ostrowski, R. P., Colohan, A. R., & Zhang, J. H. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600048 · Cited by 207
“Western blot analysis with antiVEGF antibody showed approximately 38 kDa protein band, representing VEGF homodimeric native form (Ferrara et al, 2003), which was significantly increased (2.23-fold increase, Po0.”
BackgroundInfluentialTherapeutic targeting of myeloid-derived suppressor cells
Ugel, S., Delpozzo, F., Desantis, G., Papalini, F., Simonato, F., Sonda, N., Zilio, S., & Bronte, V. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.014 · Cited by 206
“VEGF is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth, and reproductive functions, and it has been implicated in pathological angiogenesis associated with tumor development [38].”
BackgroundLin, S., Yang, G., Jiang, F., Zhou, M., Yin, S., Tang, Y., Tang, T., Zhang, Z., Zhang, W., & Jiang, X. (2019) · Advanced Science · doi:10.1002/advs.201900209 · Cited by 209
Material-based deployment enhances efficacy of endothelial progenitor cells
Silva, E. A., Kim, E.-S., Kong, H. J., & Mooney, D. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803873105 · Cited by 208
“Endothelial cells are known to be both activated by VEGF165 and to migrate up gradients of this factor established as a result of its ECM binding (26), and the VEGF165 in the scaffold in this system likely traps a high percentage of the activated cells.”
BackgroundRoles of VEGF-A signalling in development, regeneration, and tumours
Matsumoto, K., & Ema, M. (2014) · Journal of Biochemistry · doi:10.1093/jb/mvu031 · Cited by 198
Chacko, S. M., Ahmed, S., Selvendiran, K., Kuppusamy, M. L., Khan, M., & Kuppusamy, P. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00221.2010 · Cited by 201
“Since VEGF has also been shown to decrease apoptosis, delay senescence, and increase the expression of prosurvival factors, apart from its contributing role in angiogenesis (13, 33), an increase in its expression would be crucial for the survival of the cells in the infarct cardiac tissue.”
BackgroundKunig, A. M., Balasubramaniam, V., Markham, N. E., Morgan, D., Montgomery, G., Grover, T. R., & Abman, S. H. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00336.2004 · Cited by 208
Bressler, S. B. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.045 · Cited by 205
Role of hepatic resident and infiltrating macrophages in liver repair after acute injury
You, Q., Holt, M., Yin, H., Li, G., Hu, C.-J., & Ju, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.006 · Cited by 204
“VEGF is a well-documented angiogenic mediator that can promote endothelial cell growth, maturation, and survival [26].”
BackgroundManning, E. A., Ullman, J. G. M., Leatherman, J. M., Asquith, J. M., Hansen, T. R., Armstrong, T. D., Hicklin, D. J., Jaffee, E. M., & Emens, L. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0374 · Cited by 205
The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology
Stewart, M. W. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.10.001 · Cited by 204
“Subsequently, several lines of investigation have identified VEGF as a critical, rate-limiting molecule in angiogenesis.(6) Angiogenesis during embryologic growth and development requires functioning VEGF; without it, death ensues.”
BackgroundTargeting Neuropilin 1 as an Antitumor Strategy in Lung Cancer
Hong, T.-M., Chen, Y.-L., Wu, Y.-Y., Yuan, A., Chao, Y.-C., Chung, Y.-C., Wu, M.-H., Yang, S.-C., Pan, S.-H., Shih, J.-Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0001 · Cited by 197
“VEGF mediates tumor angiogenesis and promotes migration and invasion of tumor cells by directly acting on its receptors via an endothelial cell– independent pathway (8).”
BackgroundLow Doses of Ionizing Radiation Promote Tumor Growth and Metastasis by Enhancing Angiogenesis
Sofia Vala, I., Martins, L. R., Imaizumi, N., Nunes, R. J., Rino, J., Kuonen, F., Carvalho, L. M., Rüegg, C., Grillo, I. M., Barata, J. T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011222 · Cited by 194
Multiple Roles for the Receptor Tyrosine Kinase Axl in Tumor Formation
Holland, S. J., Powell, M. J., Franci, C., Chan, E. W., Friera, A. M., Atchison, R. E., McLaughlin, J., Swift, S. E., Pali, E. S., Yam, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0993 · Cited by 201
“Compelling evidence shows that vascular endothelial growth factor (VEGF) can initiate angiogenic sprouting in vivo , increasing permeability and supporting endothelial cell proliferation and survival (4).”
BackgroundAn, Y., Liu, W. J., Xue, P., Ma, Y., Zhang, L. Q., Zhu, B., Qi, M., Li, L. Y., Zhang, Y. J., Wang, Q. T., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0082-8 · Cited by 200
Angiogenesis in prostate cancer: onset, progression and imaging
Russo, G., Mischi, M., Scheepens, W., De la Rosette, J. J., & Wijkstra, H. (2012) · BJU International · doi:10.1111/j.1464-410x.2012.11444.x · Cited by 195
Voelkel, N. F., & Gomez-Arroyo, J. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0045tr · Cited by 190
“VEGF can be angiogenic or antiangiogenic depending on the ligand, the receptor, the signaling pathway and the duration of the ligand/receptor engagement(14).”
BackgroundInfluentialLi, Y.-H., Hu, C.-F., Shao, Q., Huang, M.-Y., Hou, J.-H., Xie, D., Zeng, Y.-X., & Shao, J.-Y. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-1 · Cited by 204
“Angiogenesis is an essential step for tumor growth, playing a critical role in tumor invasion and metastasis[13].”
Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy
Gacche, R. N., & Meshram, R. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.002 · Cited by 193
“A variety of tumor cell lines were found to express VEGF-A, while its receptors such as VEGFR-1 and VEGFR-2 were observed to be expressed in endothelial cells [98,127].”
BackgroundTissue engineering strategies for promoting vascularized bone regeneration
Almubarak, S., Nethercott, H., Freeberg, M., Beaudon, C., Jha, A., Jackson, W., Marcucio, R., Miclau, T., Healy, K., & Bahney, C. (2016) · Bone · doi:10.1016/j.bone.2015.11.011 · Cited by 199
“Furthermore, when these GFP+ Sca-1+/CD45− progenitor cells are encapsulated in heparin, bspRGD(15) and TGF β1 containing hyaluronic acid based hydrogel, they demonstrated in vitro vascular-like network formation and in vivo enhanced neovascular response within the hydrogel and significantly anastomosed with the host’s…”
Cardiovascular toxicity evaluation of silica nanoparticles in endothelial cells and zebrafish model
Duan, J., Yu, Y., Li, Y., Yu, Y., & Sun, Z. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.032 · Cited by 200
Zentilin, L., Puligadda, U., Lionetti, V., Zacchigna, S., Collesi, C., Pattarini, L., Ruozi, G., Camporesi, S., Sinagra, G., Pepe, M., et al. (2010) · The FASEB Journal · doi:10.1096/fj.09-143180 · Cited by 200
VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2
Zhang, Z., Neiva, K. G., Lingen, M. W., Ellis, L. M., & Nör, J. E. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.152 · Cited by 197
“Our ability to discriminate the function of VEGFR1 and VEGFR2 in vivo is hindered by the fact that both receptors play critical and complementary roles in angiogenesis.(38,39) However, in attempt to validate the concepts tested here within relevant tumor models, we exposed the endothelial cells to the CM of VEGF-produ…”
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
Li, Y.-L., Li, Y.-L., Zhao, H., Ren, X.-B., Zhao, H., & Ren, X.-B. (2016) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2015.0070 · Cited by 196
Kinnunen, K., Petrovski, G., Moe, M. C., Berta, A., & Kaarniranta, K. (2012) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2011.02179.x · Cited by 197
“Furthermore, VEGF165 is believed to be highly associated with the blood–retina barrier breakdown and pathologic intraocular neovascularization (Ferrara et al. 2003).”
BackgroundWey, J. S., Fan, F., Gray, M. J., Bauer, T. W., McCarty, M. F., Somcio, R., Liu, W., Evans, D. B., Wu, Y., Hicklin, D. J., et al. (2005) · Cancer · doi:10.1002/cncr.21145 · Cited by 194
“Vascular endothelial growth factor (VEGF) is a proangiogenic factor with roles in both physiologic and pathologic angiogenesis.(1) Also known as VEGF-A, VEGF is the prototype member of a protein family that includes VEGF-B, VEGF-C, and VEGF-D, as well as placental growth factor (PlGF).”
BackgroundAnti-vascular endothelial growth factor therapy for diabetic macular edema
Boyer, D. S., Hopkins, J. J., Sorof, J., & Ehrlich, J. S. (2013) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813512360 · Cited by 193
Green tea and its anti-angiogenesis effects
Rashidi, B., Malekzadeh, M., Goodarzi, M., Masoudifar, A., & Mirzaei, H. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.161 · Cited by 197
Schmidt, N. O., Przylecki, W., Yang, W., Ziu, M., Teng, Y. D., Kim, S. U., Black, P. M., Aboody, K. S., & Carroll, R. S. (2005) · Neoplasia · doi:10.1593/neo.04781 · Cited by 199
“Even in combination with VEGF, no effect of PlGF on NSC migration was observed (data not shown), although synergistic effects with VEGF on endothelial cells have been described [19].”
BackgroundMorabito, A., Piccirillo, M. C., Falasconi, F., De Feo, G., Del Giudice, A., Bryce, J., Di Maio, M., De Maio, E., Normanno, N., & Perrone, F. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0261 · Cited by 196
Chancellor, T. J., Lee, J., Thodeti, C. K., & Lele, T. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2010.04.011 · Cited by 194
Nanomedicine in Healing Chronic Wounds: Opportunities and Challenges
Sharifi, S., Hajipour, M. J., Gould, L., & Mahmoudi, M. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00346 · Cited by 194
Angiogenesis after ischemic stroke
Fang, J., Wang, Z., & Miao, C.-Y. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01061-2 · Cited by 186
“Mammals have five VEGF isoforms, such as VEGF-A, VEGF-B, VEGF-C, VEGF-D and PLGF, of which VEGF-A is the most original and most potent for angiogenesis [127].”
Background
Metadata
- Authors
- Ferrara, N., Gerber, H.-P., & LeCouter, J.
- Affiliations
- Genentech (US)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature Medicine
- Published
- 2003-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 669-676
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2000292756
- Cited by
- 9,591
- References
- 144
- Citations by year
- 2026: 154 · 2025: 270 · 2024: 292 · 2023: 317 · 2022: 336 · 2021: 386 · 2020: 379 · 2019: 403 · 2018: 384 · 2017: 466 · 2016: 460 · 2015: 485 · 2014: 551 · 2013: 527 · 2012: 580
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vascular endothelial growth factor, VEGF receptors, VEGFR1, VEGFR2, receptor tyrosine kinase signaling, angiogenesis, pathological angiogenesis, tumor angiogenesis, intraocular neovascularization, VEGF inhibitors, age-related macular degeneration, vascular leakage, embryonic development
- MeSH terms
- Animals, Clinical Trials as Topic, Endothelium, Vascular, Growth Substances, Humans, Lymphokines, Neovascularization, Pathologic, Oxygen, Signal Transduction, Endothelial Growth Factors, Neovascularization, Physiologic, Protein Isoforms, Intercellular Signaling Peptides and Proteins, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.